文献速递临床免疫临床生化

S100A1化学发光免疫法检测用于急性心肌梗死早期诊断与预后评估

S100A1 is a sensitive and specific cardiac biomarker for early diagnosis and prognostic assessment of acute myocardial infarction measured by chemiluminescent immunoassay.
PubMed 文献 · Clin Chim Acta · 2021-01-18

研究开发了一种自动化化学发光免疫法检测S100A1,分析性能显示检测限0.13 ng/ml、线性范围0.13-31.66 ng/ml,批内和批间重复性分别<5%和<15%。在87例急性心肌梗死或心绞痛患者中,血浆S100A1诊断敏感性高于肌酸激酶-MB和心肌肌钙蛋白T,且S100A1>1.02 ng/ml与首次PCI后不良预后相关。

要点

  • 化学发光免疫法检测S100A1的分析性能良好,检测限0.13 ng/ml。
  • 血浆S100A1对急性心肌梗死的诊断敏感性高于CK-MB和cTnT。
  • S100A1>1.02 ng/ml与首次PCI后不良预后相关。

核心结论

  • 新型化学发光免疫法检测循环S100A1有潜力用于急性心肌梗死的早期识别和预后评估。

研究设计与样本

  • 开发自动化化学发光免疫法检测S100A1并评估分析性能,包括分析灵敏度、选择性、线性范围、准确度和重复性。
  • 招募87例急性心肌梗死或心绞痛患者,探讨S100A1对早期诊断和预后评估的价值。

主要发现

  • S100A1检测限为0.13 ng/ml,线性范围为0.13-31.66 ng/ml。
  • 批内和批间重复性分别为<5%和<15%。
  • 血浆S100A1诊断敏感性高于肌酸激酶-MB和心肌肌钙蛋白T。
  • 血浆S100A1>1.02 ng/ml与急性心肌梗死患者首次PCI后不良预后显著相关。

关键数值与推荐

  • S100A1检测限0.13 ng/ml,线性范围0.13-31.66 ng/ml。
  • 批内重复性<5%,批间重复性<15%。
  • 血浆S100A1>1.02 ng/ml与首次PCI后不良预后相关。

临床怎么用

  • 该化学发光免疫法可用于检测循环S100A1,辅助急性心肌梗死的早期诊断和预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A member of the S100 family of Ca2+-binding proteins, S100A1 is highly expressed in cardiac muscle tissue. Although this protein is considered an indicator of acute myocardial infarction (AMI), high-throughput and sensitive detection methods are still urgently needed. We constructed a rapid and sensitive method for detecting S100A1 and to investigate the clinical utility of S100A1 as a biomarker for the early diagnosis of AMI and subsequent prognostic assessments. We developed an automated chemiluminescent immunoassay to detect S100A1. We then analyzed the performance of the newly developed assay including evaluation of the analytical sensitivity, analytical selectivity, linear range, accuracy and repeatability. METHODS: We recruited 87 patients with AMI or angina pectoris to explore the value of this marker for the early diagnosis and prognostic assessment. RESULTS: The chemiluminescent-immune-based S100A1 assay had functional analytical sensitivity with a detection limit of 0.13 ng/ml, and a wide linear range of 0.13-31.66 ng/ml. It also exhibited good repeatability with intra-assay and inter-assay findings of <5% and <15%, respectively. Plasma S100A1 was found to have a higher diagnostic sensitivity than conventional cardiac biomarkers (creatine kinase-MB and cardiac troponin T). The survival analysis showed that a higher concentration of plasma S100A1 (>1.02 ng/ml) was notably associated with the poor prognosis of AMI patients after first PCI. CONCLUSIONS: Measurement of circulating S100A1 concentrations with our newly developed chemiluminescent-immune-based assay shows potential for use in the clinic. This assay could enable early identification and prognostic assessment of AMI.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Li X, Wang X, Sun T, et al. S100A1 is a sensitive and specific cardiac biomarker for early diagnosis and prognostic assessment of acute myocardial infarction measured by chemiluminescent immunoassay. Clin Chim Acta. 2021. PMID: 33476588. doi:10.1016/j.cca.2021.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。